Dishman Carbogen Amics (NSE:DCAL) EBIT: ₹2,791 Mil (TTM As of Mar. 2026)


NSE:DCAL Dishman Carbogen Amics Ltd NSE:DCAL
71 GF Score
Price ₹170.02
GF Value ₹236.74
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Dishman Carbogen Amics EBIT?

Dishman Carbogen Amics NSE:DCAL -2.41% 71 EBIT is ₹2,791 Mil as of Mar. 2026. GuruFocus rates NSE:DCAL with a GF Score™ of 71/100 and a GF Value™ of ₹236.74 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Dishman Carbogen Amics's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was ₹894 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹2,791 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Dishman Carbogen Amics's annualized ROC % for the quarter that ended in Mar. 2026 was 1.26%. Dishman Carbogen Amics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 8.41%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Dishman Carbogen Amics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 5.91%.


Dishman Carbogen Amics  (NSE:DCAL) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Dishman Carbogen Amics's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=2966.4 * ( 1 - 52.87% )/( (0 + 110982.9)/ 1 )
=1398.06432/110982.9
=1.26 %

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Dishman Carbogen Amics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=3577.2/( ( (0 + max(0, 0)) + (34432.2 + max(8089.1, 0)) )/ 1 )
=3577.2/( ( 0 + 42521.3 )/ 1 )
=3577.2/42521.3
=8.41 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (0 + 0 + 0)
=0

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(6729.1 + 10191.2 + 1160.2) - (2999.7 + 0 + 6991.7)
=8089.1

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Dishman Carbogen Amics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=2790.8/47184.118
=5.91 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Dishman Carbogen Amics EBIT Related Terms


Dishman Carbogen Amics EBIT Historical Data

* Premium members only.

The historical data trend for Dishman Carbogen Amics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dishman Carbogen Amics EBIT Chart

Dishman Carbogen Amics Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 349.70 198.00 -88.50 1,787.70 2,790.80

Dishman Carbogen Amics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 698.20 814.30 728.70 353.50 894.30

NSE:DCAL vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Dishman Carbogen Amics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dishman Carbogen Amics EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dishman Carbogen Amics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Dishman Carbogen Amics's EV-to-EBIT falls into.


NSE:DCAL
71GF Score
Dishman Carbogen Amics Ltd NSE:DCAL
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Dishman Carbogen Amics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹2,791 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ₹2,791 Mil mean?
Dishman Carbogen Amics (NSE:DCAL) has a EBIT of ₹2,791 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Dishman Carbogen Amics.
Is Dishman Carbogen Amics' EBIT too high?
Dishman Carbogen Amics' current EBIT is ₹2,791 Mil. Overall, Dishman Carbogen Amics has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Dishman Carbogen Amics' EBIT compare to VRTX and REGN?
Dishman Carbogen Amics' EBIT of ₹2,791 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Dishman Carbogen Amics. Dishman Carbogen Amics's current EBIT is ₹2,791 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dishman Carbogen Amics stock overvalued right now?
Based on GuruFocus' analysis, Dishman Carbogen Amics (NSE:DCAL) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹236.74, compared to a current price of ₹170.02 — trading 28.2% below its estimated fair value. The current EBIT is ₹2,791 Mil. Dishman Carbogen Amics' overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Dishman Carbogen Amics (NSE:DCAL), the current EBIT is ₹2,791 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Dishman Carbogen Amics (NSE:DCAL) Overvalued in 2026?

Based on GuruFocus' analysis, Dishman Carbogen Amics stock appears to be undervalued. The current stock price of ₹170.02 is trading 28.2% below its estimated GF Value™ of ₹236.74. GuruFocus considers Dishman Carbogen Amics to be Modestly Undervalued.

Key valuation signals for NSE:DCAL:

  • EBIT: ₹2,791 Mil
  • GF Value™: ₹236.74 vs. price of ₹170.02 (28.2% below fair value)
  • GF Score™: 71/100 with 3 warning signs

No single metric tells the full story. See the NSE:DCAL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Dishman Carbogen Amics Business Description

Other Exchanges 540701:India
Address Iscon-Bopal Road, Dishman Corporate House, Ambli, Ahmedabad, GJ, IND, 380 058
Dishman Carbogen Amics Ltd is a biotechnology company that provides contract research and manufacturing services for pharmaceutical companies. It manufactures bulk drugs, specialty chemicals, and outsourced goods. Additionally, the company produces vitamins, such as vitamin D2 and vitamin D3, reagents, antiseptics and disinfectants, transfer catalysts, personal-care ingredients, pharma intermediates, and ammonium and phosphonium high-purity solid Quats. The business generates the vast majority of its revenue in India.
71GF Score

Get the complete analysis for NSE:DCAL

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹170.02
Price
₹236.74
GF Value